In 2009, Fujimura and colleagues detected CYP3A4 in healthy prostate and prostate cancer tissue and found that prostate cancer cells had a lower CYP3A4 immunoreactivity score (sum of the proportion of positively stained cells and staining intensity; 3.6 ± 2.6) compared to the benign epithelium (4.5 ± 2.1; P < 0.0001). This evidence concerns the gene CYP3A4 and Familial prostate cancer.